Here’s two new ETFs for Canadian investors

This month we take a look at a new healthcare ETF from TD Asset Management, plus a very unique ETF from Horizons that focus on companies looking to develop psychedelic drugs for the treatment of mental illness.
TD Asset Management recently launched the TD Global… Read More

AbbVie’s diversification pays off

We continue to see attractive investment opportunities for our subscribers in top drug stocks—and that includes AbbVie Inc.
Over the years, we’ve found that spinoffs are about as close as you can get to a sure thing in investing. It’s one key reason why we think… Read More

Dividend Advisor Hotline – Friday, May 14, 2021

ALGONQUIN POWER & UTILITIES CORP., $18.60, Toronto symbol AQN, is a buy.

Algonquin has two main businesses: the Regulated Services Group provides regulated electricity, gas, water distribution and wastewater collection services to 1.9 million customers in Canada, the U.S., Chile and Bermuda; and the Renewable Power… Read More

Q: Compass Pathways looks to be in an interesting new market for magic mushroom drugs. What do you think of the shares as an investment? Thank you.

A: Compass Pathways plc (ADR), $36.19, symbol CMPS on Nasdaq (Shares outstanding: 36.7 million; Market cap: $1.4 billion; www.compasspathways.com), was founded in 2015. The company is now testing the psychoactive compound psilocybin, sometimes referred to as “magic mushrooms,” as a therapy for treatment-resistant depression, or… Read More